gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Coagulation factor III

Thromboplastin, tissue factor
This gene encodes coagulation factor III which is a cell surface glycoprotein. This factor enables cells to initiate the blood coagulation cascades, and it functions as the high-affinity receptor for the coagulation factor VII. The resulting complex provides a catalytic event that is responsible for initiation of the coagulation protease cascades by specific limited proteolysis. Unlike the other cofactors of these protease cascades, which circulate as nonfunctional precursors, this factor is a potent initiator that is fully functional when expressed on cell surfaces. There are 3 distinct domains of this factor: extracellular, transmembrane, and cytoplasmic. This protein is the only one in the coagulation pathway for which a congenital deficiency has not been described. Alternate splicing results in multiple transcript variants.[provided by RefSeq, May 2010] (from NCBI)
Top mentioned proteins: HAD, CAN, AGE, V1a, Plasminogen
Papers using Thromboplastin antibodies
CLEC-2 activates Syk through dimerization
Heemskerk Johan W. M. et al., In Cellular and Molecular Life Sciences, 2009
... Human α-thrombin was obtained from Enzyme Research Laboratories, recombinant human tissue factor came from Dade Behring, abciximab (reopro) from Centocor; tirofiban (aggrastat) from Merck Sharp & Dohme, and ...
Upstream and downstream of mTOR
Yang Zhihong et al., In BMC Cardiovascular Disorders, 2003
... tumor necrosis factor-α (TNF-α) was purchased from R & D, France); monoclonal mouse anti-TF antibody and tissue factor activity kit were purchased from American Diagnostica Inc (Socochim, Lausanne, Switzerland); ...
Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide
Samad Fahumiya et al., In Nature medicine, 1995
... Disulfide isomerization switches tissue factor from coagulation to cell signaling ...
Papers on Thromboplastin
Cofactor Independent Human Antiphospholipid Antibodies Induce Venous Thrombosis in Mice.
Lackner et al., Mainz, Germany. In J Thromb Haemost, Feb 2016
Thrombus formation depends on tissue factor activation.
Coagulation management in trauma-associated coagulopathy: allogenic blood products versus coagulation factor concentrates in trauma care.
Weber et al., Frankfurt am Main, Germany. In Curr Opin Anaesthesiol, Feb 2016
Standard coagulation tests such as prothrombin time and activated partial thromboplastin time are commonly used, but these tests are inappropriate for monitoring and guiding therapy in trauma patients.
Assessment of platelet-derived thrombogenicity by the total thrombus-formation analysis system in coronary artery disease patients on antiplatelet therapy.
Ogawa et al., Kumamoto, Japan. In J Thromb Haemost, Feb 2016
The total thrombus-formation analysis system (T-TAS) was developed for quantitative analysis of platelet thrombus formation using microchips with thrombogenic surfaces (collagen, PL chip; collagen plus tissue factor, AR chip).
Inhibition of complement component C5 prevents clotting in an ex vivo model of xenogeneic activation of coagulation.
Tiede et al., Hannover, Germany. In Xenotransplantation, Feb 2016
The activation of PAEC (E-Selectin, tissue factor, ICAM-1, ICAM-2, VCAM-1) was studied after incubation with human serum.
Tissue Factor Pathway Inhibitor: Multiple Anticoagulant Activities for a Single Protein.
Mast, Milwaukee, United States. In Arterioscler Thromb Vasc Biol, Jan 2016
Tissue factor (TF) pathway inhibitor (TFPI) is an anticoagulant protein that inhibits early phases of the procoagulant response.
Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies.
Ataga et al., Chapel Hill, United States. In Blood Rev, Jan 2016
Patients exhibit increased platelet activation, high plasma levels of markers of thrombin generation, depletion of natural anticoagulant proteins, abnormal activation of the fibrinolytic system, and increased tissue factor expression, even in the non-crisis "steady state."
Thromboelastography in Selected Avian Species.
Bertelsen et al., In J Avian Med Surg, Dec 2015
Activated partial thromboplastin time, prothrombin time, and fibrinogen were measured as a means of comparison.
Acquired haemophilia: an overview for clinical practice.
Knöbl et al., Washington, D.C., United States. In Eur J Haematol, Dec 2015
Diagnosis involves an isolated prolongation of the activated partial thromboplastin time, without correction in mixing studies, low FVIII activity levels and evidence of a FVIII inhibitor.
Bivalirudin as an Alternative to Heparin for Anticoagulation in Infants and Children.
Buck, Charlottesville, United States. In J Pediatr Pharmacol Ther, Nov 2015
The case reports and clinical studies currently available suggest that bivalirudin is as effective as heparin at reaching target activated clotting times or activated partial thromboplastin times, with equivalent or the lower rates of bleeding or thromboembolic complications.
Pancreatic cancer and thromboembolic disease, 150 years after Trousseau.
Andrén-Sandberg et al., Lund, Sweden. In Hepatobiliary Surg Nutr, Oct 2015
The exact pathophysiological mechanisms are still partly understood, but it is known that pancreatic cancer induces a prothrombotic and hypercoagulable state and genetic events involved in neoplastic transformation (e.g., KRAS, c-MET, p53), procoagulant factors [e.g., tissue factor (TF), platelet factor 4 (PF4), plasminogen activator inhibitor type 1 (PAI-1)], mucin production (e.g., through activation of P- and L-selectin) and pro-inflammatory factors [e.g., cytokines, cyclooxygenase-2 (COX-2)] may be implicated.
Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.
Kreuzer et al., Biberach an der Riß, Germany. In Lancet, Sep 2015
Reversal of diluted thrombin time (dTT), ecarin clotting time (ECT), activated partial thromboplastin time (aPTT), and thrombin time (TT) were secondary endpoints assessed by measuring the area under the effect curve from 2 h to 12 h (AUEC2-12) after dabigatran etexilate ingestion on days 3 and 4.
Retinoic Acid Differentially Regulates the Migration of Innate Lymphoid Cell Subsets to the Gut.
Kim et al., West Lafayette, United States. In Immunity, Aug 2015
This process is regulated by mucosal dendritic cells and the gut-specific tissue factor retinoic acid (RA).
A Monovalent Chimpanzee Adenovirus Ebola Vaccine - Preliminary Report.
Hill et al., Oxford, United Kingdom. In N Engl J Med, Feb 2015
Prolonged activated partial-thromboplastin times and transient hyperbilirubinemia were observed in 4 and 8 participants, respectively.
Phenotypic screening of the ToxCast chemical library to classify toxic and therapeutic mechanisms.
Houck et al., United States. In Nat Biotechnol, 2014
The endpoints measured can be closely linked to in vivo outcomes, such as the upregulation of tissue factor in endothelial cell systems by compounds linked to the risk of thrombosis in vivo.
Preeclampsia: the role of tissue factor and tissue factor pathway inhibitor.
Sant'Ana Dusse et al., Belo Horizonte, Brazil. In J Thromb Thrombolysis, 2012
Preeclampsia: the role of tissue factor and tissue factor pathway inhibitor.
Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer.
Mackman et al., Chapel Hill, United States. In Blood, 2012
Only TF-positive cell lines activated coagulation in nude mice, and this activation was abolished by an anti-human TF Ab.
Caffeine induces endothelial tissue factor expression via phosphatidylinositol 3-kinase inhibition.
Tanner et al., Zürich, Switzerland. In Thromb Haemost, 2012
Caffeine enhances TNF-alpha-induced endothelial TF protein expression as well as surface activity by inhibition of PI3K signalling.
Tissue factor proangiogenic signaling in cancer progression.
Ruf et al., Los Angeles, United States. In Thromb Res, 2012
Here we review the evidence that TF-dependent signaling is the major driver of primary tumor growth.
Tissue factor isoforms in cancer and coagulation: may the best isoform win.
Versteeg et al., Leiden, Netherlands. In Thromb Res, 2012
In this review, we aim to present a side-by-side evaluation of normally-spliced, full length TF (flTF) and asTF with regard to coagulant function, atherosclerosis, tumor progression and malignancy-associated thrombosis.
Tissue factor-protease-activated receptor 2 signaling promotes diet-induced obesity and adipose inflammation.
Samad et al., San Diego, United States. In Nat Med, 2010
Tissue factor, the initiator of the coagulation cascade, mediates coagulation factor VIIa-dependent activation of protease-activated receptor 2 (PAR2).
share on facebooktweetadd +1mail to friends